Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.

Tarsus (NASDAQ:TARS) is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Armentum Partners

Horowitz Group

Vivo Capital

Aperture Venture Partners

Visionary Venture Fund

Flying L Partners

Frazier Healthcare Partners

The first and only FDA-approved treatment for Demodex blepharitis (DB) is now available! We’re delighted to introduce this new therapeutic to the eye care community and thrilled at its potential to help many patients living with this disease.

We are so appreciative of our superstar Tarsus team and the many partners who worked diligently to make this important milestone happen. 

Read the full press release here: https://lnkd.in/eEQW3SEv

🌺 Aloha from the Hawaiian Eye & Retina 2024 Meeting! 

We love kicking off the New Year by attending this important and engaging meeting! This year, we had the privilege of connecting with leading experts in eye care across a variety of different platforms to share experiences about Demodex blepharitis and eyelid health. We appreciate the unique perspectives and compelling discussion and look forward to continuing the dialogue as we move further into 2024. 

Today, we commemorate the incredible life and impact of Dr. Martin Luther King Jr.

His unwavering dedication to justice, equality, and unity continues to inspire us. Dr. King had a vision for a brighter, more inclusive future, and we strive to honor that vision in everything we do at Tarsus.

This #MLKDay, we encourage our Tarsans to volunteer in their communities and reflect on Dr. King's commitments to peace, service, and education.

The Tarsus crew celebrated the holidays and rang in the New Year traveling, relaxing and spending time with loved ones!

We prioritize the health and well-being of our Tarsans and look forward to this important recharge break at the end of each year. Swipe through to see some highlights of our winter wellness week.

Discover more about the values that shape our culture: https://lnkd.in/eGeFU8_E

As we bid farewell to 2023, we’d like to reflect on what an incredible year it’s been.

2023 was a milestone year – we received FDA approval for the first and only treatment for Demodex blepharitis and just a few weeks into launch, we are well on our way to helping millions of potential patients. We experienced tremendous growth as an organization, more than doubling in size, and we were recognized by numerous independent companies as a great place to work.

We are grateful to our investigators, eye care provider partners, patients and our passionate team of Tarsans who helped us get to where we are today.

We are inspired and motivated to start 2024 and continue to deliver on our vision to make a meaningful difference in eye care and to the patients we serve. We wish everyone a happy and healthy holiday season.

See here for XDEMVY prescribing info: https://bit.ly/3Rrf4YB

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				57.03M -	25.82M 54.73%	17.45M 32.42%
cost of revenue				2.08M -	955K 53.98%	1.59M 66.81%
gross profit				54.95M -	24.86M 54.76%	15.85M 36.23%
selling and marketing expenses
general and administrative expenses	449K -	1.14M 153.01%	8.17M 619.37%	25.40M 210.78%	44.95M 76.99%
selling general and administrative expenses	449K -	1.14M 153.01%	8.17M 619.37%	25.40M 210.78%	44.95M 76.99%	108.70M 141.83%
research and development expenses	901K -	3.16M 250.94%	18.83M 495.38%	41.71M 121.57%	42.62M 2.19%	50.31M 18.04%
other expenses				-73K -	86K 217.81%	-102K 218.60%
cost and expenses	1.35M -	4.30M 218.37%	27.00M 528.15%	69.18M 156.26%	88.53M 27.96%	160.60M 81.42%
operating expenses	1.35M -	4.30M 218.37%	27.00M 528.15%	67.11M 148.57%	87.57M 30.49%	159.01M 81.58%
interest expense			188K -		2.20M -	3.35M 52.16%
ebitda	-1.35M -	-3.93M 191.33%	-26.90M 584.53%	-10.58M 60.68%	-59.13M 458.91%	-142.28M 140.64%
operating income	-1.35M -	-4.30M 218.37%	-27.00M 528.15%	-12.16M 54.97%	-62.71M 415.85%	-143.16M 128.28%
depreciation and amortization	1K -	368K 36,700%	96K 73.91%	1.58M 1,543.75%	3.58M 127.19%	877K 75.54%
total other income expenses net	32K -	-371K 1,259.38%	188K 150.67%	-1.61M 959.04%	617K 138.20%	7.26M 1,077.47%
income before tax	-1.32M -	-4.67M 254.25%	-26.81M 474.21%	-13.77M 48.63%	-62.09M 350.88%	-135.89M 118.85%
income tax expense	1K -	1K 0%	1K 0%	55K 5,400%	-4K 107.27%
net income	-1.32M -	-4.67M 254.06%	-26.81M 474.11%	-13.83M 48.43%	-62.09M 349.06%	-135.89M 118.86%
weighted average shs out	4.29M -	2.36M 44.86%	6.21M 162.72%	20.55M 231.12%	24.62M 19.78%	29.38M 19.35%
weighted average shs out dil	4.29M -	2.36M 44.86%	6.21M 162.72%	20.55M 231.12%	24.62M 19.78%	29.38M 19.35%
eps	-0.31 -	-1.98 538.71%	-4.32 118.18%	-0.67 84.49%	-2.52 276.12%	-4.62 83.33%
epsdiluted	-0.31 -	-1.98 538.71%	-4.32 118.18%	-0.67 84.49%	-2.52 276.12%	-4.62 83.33%

COM:TARSUSRX

Tarsus Pharmaceuticals, Inc.

Last Close

46.40

22/11 21:00

Market Cap

1.07B

Beta: -

Volume Today

589.21K

Avg: -

Preview